JP7842011B2 - ヘテロ二量体タンパク質 - Google Patents

ヘテロ二量体タンパク質

Info

Publication number
JP7842011B2
JP7842011B2 JP2022519303A JP2022519303A JP7842011B2 JP 7842011 B2 JP7842011 B2 JP 7842011B2 JP 2022519303 A JP2022519303 A JP 2022519303A JP 2022519303 A JP2022519303 A JP 2022519303A JP 7842011 B2 JP7842011 B2 JP 7842011B2
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
heterodimer protein
antibody
heterodimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022519303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549351A (ja
JP2022549351A5 (https=
Inventor
ダン・シッダールタ・チャンド
ザーラ・ジャワド
ヴァロニカ・フランシスカ・イルコウ
Original Assignee
アジェナス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェナス インコーポレイテッド filed Critical アジェナス インコーポレイテッド
Publication of JP2022549351A publication Critical patent/JP2022549351A/ja
Publication of JP2022549351A5 publication Critical patent/JP2022549351A5/ja
Application granted granted Critical
Publication of JP7842011B2 publication Critical patent/JP7842011B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022519303A 2019-09-27 2020-09-28 ヘテロ二量体タンパク質 Active JP7842011B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906918P 2019-09-27 2019-09-27
US62/906,918 2019-09-27
PCT/US2020/053114 WO2021062382A1 (en) 2019-09-27 2020-09-28 Heterodimeric proteins

Publications (3)

Publication Number Publication Date
JP2022549351A JP2022549351A (ja) 2022-11-24
JP2022549351A5 JP2022549351A5 (https=) 2023-10-06
JP7842011B2 true JP7842011B2 (ja) 2026-04-07

Family

ID=75166489

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519303A Active JP7842011B2 (ja) 2019-09-27 2020-09-28 ヘテロ二量体タンパク質

Country Status (10)

Country Link
US (2) US20210130495A1 (https=)
EP (1) EP4034570A4 (https=)
JP (1) JP7842011B2 (https=)
KR (1) KR20220069935A (https=)
CN (1) CN114787186B (https=)
AU (1) AU2020355253A1 (https=)
BR (1) BR112022004789A2 (https=)
IL (1) IL291618A (https=)
MX (1) MX2022003149A (https=)
WO (1) WO2021062382A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140079689A1 (en) 2011-02-04 2014-03-20 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
CN110028584A (zh) 2018-01-12 2019-07-19 北京科昕生物科技有限公司 针对egfr蛋白和met蛋白的双特异性抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE299938T1 (de) * 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2843158A1 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
BR112014010580B1 (pt) * 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
ES2876009T3 (es) * 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
MY203000A (en) * 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
KR20200014379A (ko) * 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
SG11202104136YA (en) * 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140079689A1 (en) 2011-02-04 2014-03-20 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
CN110028584A (zh) 2018-01-12 2019-07-19 北京科昕生物科技有限公司 针对egfr蛋白和met蛋白的双特异性抗体

Also Published As

Publication number Publication date
WO2021062382A1 (en) 2021-04-01
CA3151574A1 (en) 2021-04-01
JP2022549351A (ja) 2022-11-24
US20240360249A1 (en) 2024-10-31
MX2022003149A (es) 2022-04-06
AU2020355253A1 (en) 2022-03-24
EP4034570A4 (en) 2023-10-25
CN114787186B (zh) 2025-06-03
CN114787186A (zh) 2022-07-22
KR20220069935A (ko) 2022-05-27
EP4034570A1 (en) 2022-08-03
US20210130495A1 (en) 2021-05-06
IL291618A (en) 2022-05-01
BR112022004789A2 (pt) 2022-06-21

Similar Documents

Publication Publication Date Title
US20210324085A1 (en) Aspgr antibodies and uses thereof
JP7022123B2 (ja) Ｃｄ３に対する二重特異性抗体
CN106164095B (zh) 多特异性抗体
EP3174897B1 (en) Multispecific antibodies
EP3204415B1 (en) Bispecific antibodies against cd3epsilon and ror1
KR101586128B1 (ko) 디술피드 안정화 ― Ｆｖ 단편을 포함하는 이중특이적 항체
TW202212361A (zh) 結合cd3之抗體
EP3594232A1 (en) Methods and means for the production of ig-like molecules
CN107922503A (zh) 一种pdl‑1抗体、其药物组合物及其用途
KR20180073561A (ko) 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
CN108350048A (zh) 具有SIRP-α结构域或其变体的构建体
JP2017525690A (ja) 二重特異性ｔ細胞活性化抗原結合分子
US20240360249A1 (en) Heterodimeric proteins
JP2022532414A (ja) 新規変形免疫グロブリンｆｃ融合タンパク質及びその用途
JP2022535060A (ja) 選択的に切断可能なリンカーを有する二重特異性結合構築物
CA3151574C (en) Heterodimeric proteins
HK40077576B (zh) 异二聚体蛋白
HK40077576A (zh) 异二聚体蛋白
WO2025247301A1 (en) Novel antibodies specific for cd98 heavy chain and methods of uses thereof
WO2025237931A1 (en) Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
HK40112962A (zh) 抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法
WO2025099252A1 (en) Co-delivery system
EP4724477A1 (en) Circularized antibody molecules
CN119486756A (zh) 包含结合γ-δ T细胞受体的抗体的组合物
HK40020922A (en) Methods and means for the production of ig-like molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260326

R150 Certificate of patent or registration of utility model

Ref document number: 7842011

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150